193 related articles for article (PubMed ID: 31496700)
1. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
Liu X; Ghosh D
Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
[TBL] [Abstract][Full Text] [Related]
2. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
Liu H; Qian F
Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
[TBL] [Abstract][Full Text] [Related]
3. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
[TBL] [Abstract][Full Text] [Related]
4. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.
Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P
ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
Mehta A; Dalle Vedove E; Isert L; Merkel OM
Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
[TBL] [Abstract][Full Text] [Related]
6. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
[TBL] [Abstract][Full Text] [Related]
7. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
[TBL] [Abstract][Full Text] [Related]
8. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.
Li R; Ng TSC; Wang SJ; Prytyskach M; Rodell CB; Mikula H; Kohler RH; Garlin MA; Lauffenburger DA; Parangi S; Dinulescu DM; Bardeesy N; Weissleder R; Miller MA
Nat Nanotechnol; 2021 Jul; 16(7):830-839. PubMed ID: 33958764
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.
Xiong X; Rao G; Roy RV; Zhang Y; Means N; Dey A; Tsaliki M; Saha S; Bhattacharyya S; Dhar Dwivedi SK; Rao CV; McCormick DJ; Dhanasekaran D; Ding K; Gillies E; Zhang M; Yang D; Bhattacharya R; Mukherjee P
FASEB J; 2020 Sep; 34(9):12024-12039. PubMed ID: 32692445
[TBL] [Abstract][Full Text] [Related]
10. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
[TBL] [Abstract][Full Text] [Related]
11. High-content, full genome siRNA screen for regulators of oncogenic HRAS-driven macropinocytosis.
Fennell M; Commisso C; Ramirez C; Garippa R; Bar-Sagi D
Assay Drug Dev Technol; 2015 Sep; 13(7):347-55. PubMed ID: 26267765
[TBL] [Abstract][Full Text] [Related]
12. KRAS
Hobbs GA; Der CJ
Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
[TBL] [Abstract][Full Text] [Related]
13. In situ exploration of characteristics of macropinocytosis and size range of internalized substances in cells by 3D-structured illumination microscopy.
Jin J; Shen Y; Zhang B; Deng R; Huang D; Lu T; Sun F; Xu S; Liang C
Int J Nanomedicine; 2018; 13():5321-5333. PubMed ID: 30254437
[TBL] [Abstract][Full Text] [Related]
14. Transcription Factor Eb Is Required for Macropinocytosis-Mediated Growth Recovery of Nutrient-Deprived Kras-Mutant Cells.
Jeong S; Byun JK; Cho SJ; Chin J; Lee IK; Choi YK; Park KG
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400219
[TBL] [Abstract][Full Text] [Related]
15. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
[TBL] [Abstract][Full Text] [Related]
16. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
18. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis.
Seguin L
Subcell Biochem; 2022; 98():189-204. PubMed ID: 35378709
[TBL] [Abstract][Full Text] [Related]
19. U1 Adaptors Suppress the
Tsang AT; Dudgeon C; Yi L; Yu X; Goraczniak R; Donohue K; Kogan S; Brenneman MA; Ho ES; Gunderson SI; Carpizo DR
Mol Cancer Ther; 2017 Aug; 16(8):1445-1455. PubMed ID: 28377488
[TBL] [Abstract][Full Text] [Related]
20. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]